InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use

Authors :: C.E. Jones
MeiLan K. Han
Dave Singh
Mark T. Dransfield
David A. Lomas
G.J. Criner
Peter Lange
Robert A. Wise
Fernando J. Martinez
Sally Kilbride
Steven Pascoe
Dmg Halpin
David A. Lipson
Source :: A24. COPD: THERAPY, IMAGING, AND MOLECULAR MARKERS.
Publication Year :: 2019
Publisher :: American Thoracic Society, 2019.

Subjects :: medicine.medical_specialty
Medication use
COPD
business.industry
Inhaler
Impact study
medicine.disease
Fluticasone furoate/vilanterol
Fluticasone propionate
UMECLIDINIUM/VILANTEROL
Internal medicine
medicine
In patient
business
medicine.drug

Tools